Barr Allegra-D Generic Receives Final Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
A launch of the generic fexofenadine/pseudoephedrine combination would be "at risk" because of ongoing patent litigation with Sanofi-Aventis. Final ANDA approval follows resolution of a dispute between Barr and FDA over 180-day exclusivity for the product.
You may also be interested in...
Teva Launches Generic Allegra Tablets Despite Patent Litigation
Marketing agreement between Barr, which is waiving its exclusivity, and Teva would allow the companies to share the litigation hazard of the "at risk" launch.
Teva Launches Generic Allegra Tablets Despite Patent Litigation
Marketing agreement between Barr, which is waiving its exclusivity, and Teva would allow the companies to share the litigation hazard of the "at risk" launch.
Senate Health Members Take A Time-Out From Crawford Vote To Discuss Plan B
Committee Chair Enzi (R-Wyo.) postpones panel's vote on Crawford's nomination for FDA commissioner "to provide more time to address issues that have been raised on both sides of the aisle."